Combo OTC Drug Labeling Deadlines To Be Addressed In Final Monographs
This article was originally published in The Rose Sheet
Executive Summary
FDA will take into account OTC labeling regulation compliance deadlines when publishing final monographs that could subject combination products to frequent relabeling, the agency says in a June 20 Federal Register notice extending by one year implementation provisions for specific types of OTCs.